An anti-inflammatory liquid composition for covering oral mucosa includes: a rosin; a shellac; and a solvent. A content of the rosin is 1 wt % or more and 15 wt % or less relative to a total amount of the composition. A content of the shellac is 35 wt % or more and 45 wt % or less relative to the total amount of the composition. A total content of the rosin, the shellac, and a copal is 45 wt % or more and 55 wt % or less relative to the total amount of the composition.

An anti-inflammatory liquid composition for covering oral mucosa includes: a rosin; a shellac; and a solvent. A content of the rosin is 1 wt % or more and 15 wt % or less relative to a total amount of the composition. A content of the shellac is 35 wt % or more and 45 wt % or less relative to the total amount of the composition. A total content of the rosin, the shellac, and a copal is 45 wt % or more and 55 wt % or less relative to the total amount of the composition.

The invention relates to a coated balloon catheter with a catheter substrate and a coating on the catheter substrate. The coating comprises a pharmaceutically active ingredient embedded in a binder matrix. The binder matrix consists of a polyethylene glycol-polyvinyl alcohol copolymer (PEG-PVA copolymer) and optionally shellac or a shellac derivative and additional pharmaceutically acceptable additives. A composition for coating the balloon catheter comprises the pharmaceutically active ingredient and a binder consisting of a PEG-PVA copolymer and optionally shellac or a shellac derivative. The active ingredient and the binder are dissolved in a solvent consisting of water, DMSO and at least one additional organic solvent indefinitely miscible with water.

The invention relates to a coated balloon catheter with a catheter substrate and a coating on the catheter substrate. The coating comprises a pharmaceutically active ingredient embedded in a binder matrix. The binder matrix consists of a polyethylene glycol-polyvinyl alcohol copolymer (PEG-PVA copolymer) and optionally shellac or a shellac derivative and additional pharmaceutically acceptable additives. A composition for coating the balloon catheter comprises the pharmaceutically active ingredient and a binder consisting of a PEG-PVA copolymer and optionally shellac or a shellac derivative. The active ingredient and the binder are dissolved in a solvent consisting of water, DMSO and at least one additional organic solvent indefinitely miscible with water.

A seed or seedling is coated with underivatized guar, cationic hydroxypropyl guar, polyacrylamide, poly(methacrylic acid), poly(acrylic acid), polyacrylate, poly(ethylene glycol), polyethyleneoxide, poly(vinyl alcohol), polyglycerol, polytetrahydrofuran, polyamide, hydroxypropyl guar, carboxymethyl guar, carboxymethylhydroxypropyl guar, underivatized starch, cationic starch, corn starch, wheat starch, rice starch, potato starch, tapioca, waxy maize, sorghum, waxy sarghum, sago, dextrin, chitin, chitosan, xanthan gum, carageenan gum, gum karaya, gum arabic, pectin, cellulose, hydroxycellulose, hydroxyalkyl cellulose, hydroxyethyl cellulose, carboxymethylhydroxyethyl cellulose, or hydroxypropyl cellulose, the coated seed or seedling having a shelf-life at room temperature in ambient conditions in an unsealed container to at least two months.

A seed or seedling is coated with underivatized guar, cationic hydroxypropyl guar, polyacrylamide, poly(methacrylic acid), poly(acrylic acid), polyacrylate, poly(ethylene glycol), polyethyleneoxide, poly(vinyl alcohol), polyglycerol, polytetrahydrofuran, polyamide, hydroxypropyl guar, carboxymethyl guar, carboxymethylhydroxypropyl guar, underivatized starch, cationic starch, corn starch, wheat starch, rice starch, potato starch, tapioca, waxy maize, sorghum, waxy sarghum, sago, dextrin, chitin, chitosan, xanthan gum, carageenan gum, gum karaya, gum arabic, pectin, cellulose, hydroxycellulose, hydroxyalkyl cellulose, hydroxyethyl cellulose, carboxymethylhydroxyethyl cellulose, or hydroxypropyl cellulose, the coated seed or seedling having a shelf-life at room temperature in ambient conditions in an unsealed container to at least two months.

A medical device includes a device body preferably made of a material susceptible to corrosion or biodegradation and a shellac coating. The device body is at least partially covered by the shellac coating. The shellac coating has a thickness from 0.1 μm to 20 μm. A method for manufacturing the medical device includes the steps of providing the device body and applying the shellac coating onto a surface of the device body.

A medical device includes a device body preferably made of a material susceptible to corrosion or biodegradation and a shellac coating. The device body is at least partially covered by the shellac coating. The shellac coating has a thickness from 0.1 μm to 20 μm. A method for manufacturing the medical device includes the steps of providing the device body and applying the shellac coating onto a surface of the device body.

A method of forming a core-shell polymer nanoparticle encapsulating an active agent is disclosed, including the use of a multi-solvent system in which to dissolve the active agent and a polymer prior to their precipitation using an antisolvent. The preferred use of an organic solvent system comprising two or more organic solvents allows for a high degree of control, as compared with the use of a single solvent, and enables the active agent to be precipitated more or less simultaneously with, or just prior to, the polymer.

The present invention relates to a method for coating catheter balloons with the pharmacological agent paclitaxel and the biological and biodegradable polymer composition shellac and optionally further components. Moreover the present invention relates to paclitaxel and shellac coated catheter balloons obtained according to the coating methods disclosed herein as well as the use of such coated catheter balloons for the short time release of the pharmaceutically active agent paclitaxel for prophylaxis and treatment of restenosis especially restenosis caused by angioplasty. The coated catheter balloons can be used alone or in combination with a coated or uncoated stent crimped on the catheter balloon before or after the coating with shellac and paclitaxel.